Rare Diseases News 15 October 2025

Rhythm Pharmaceuticals (RYTM) Hits Record High on Rare-Disease Breakthrough: Latest News, Stock Forecast and Analyst Outlook

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) stock is on a tear. On 11 December 2025, shares surged to a new all‑time high after the company reported encouraging mid‑stage data in Prader‑Willi syndrome (PWS) and investors refocused on a growing obesity franchise

11 December 2025

Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Bottom Line: Avidity Biosciences’ stock is set to explode higher on Novartis’s $12 billion buyout, capping off a dramatic run fueled by breakthrough science and takeover buzz. The high-premium deal underscores the massive value of RNA therapeutics for rare diseases

26 October 2025

Biotech · Mergers & Acquisitions · Pharmaceuticals · Rare Diseases · Stock Market

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Deal Details: Novo Licenses Omeros’s MASP-3 Inhibitor On Oct. 15, Novo Nordisk and Seattle-based Omeros announced a definitive asset purchase and license agreement. Under the terms, Novo gains exclusive global rights to zaltenibart (OMS906) for all indications. Omeros will receive $340

15 October 2025

Biotech Industry · Business Analysis · Mergers & Acquisitions · NASDAQ:AKRO · NASDAQ:OMER · NYSE:NVO · Pharma News · Rare Diseases

Rare Diseases News 15 October 2025 - 11 December 2025

Rhythm Pharmaceuticals (RYTM) Hits Record High on Rare-Disease Breakthrough: Latest News, Stock Forecast and Analyst Outlook

Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know